Story perspectives

AstraZeneca Falls 7%, Bristol Myers Rises 3.8% on Merger Rumors

8/4/2026

Summary

Story summary

AstraZeneca and Bristol Myers Squibb shares changed after merger talk reports, with AstraZeneca down >7% and Bristol Myers Squibb up 3.8%.
Together the firms are valued at about $400 billion, creating the world’s fourth-largest pharmaceutical group.
Talks have run for months with no terms set and could be delayed or fail.
AstraZeneca CEO Pascal Soriot says the merger could lift U.S. sales toward an $80 billion 2030 target.

History

Historical Context

Glaxo Wellcome and SmithKline Beecham announced their merger in January 2000 and completed it on 27 December 2000, creating GlaxoSmithKline. The deal sparked a wave of large-scale consolidations, including GSK’s 2018 consumer-health joint venture with Pfizer and its 2022-2026 acquisition spree. As of February 2026 GSK holds a $122.6 billion market capitalisation, underscoring why AstraZeneca and Bristol Myers Squibb are pursuing a comparable merger.

1 of 2

Story summary

AstraZeneca and Bristol Myers Squibb shares changed after merger talk reports, with AstraZeneca down >7% and Bristol Myers Squibb up 3.8%.
Together the firms are valued at about $400 billion, creating the world’s fourth-largest pharmaceutical group.
Talks have run for months with no terms set and could be delayed or fail.
AstraZeneca CEO Pascal Soriot says the merger could lift U.S. sales toward an $80 billion 2030 target.

1 / 2